source
- Evommune's lead drug fails in chronic hives trial, shares tumble over 30%Evommune reported its first major trial readout since going public last year, focusing on its lead candidate for chronic spontaneous urticaria, a condition where patients experience recurring hives…
- BioCryst to shut internal drug discovery and close Alabama research siteBioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…